The Play On Vir Biotechnology

2025-09-03 15:14:58 ET

Shares of infectious disease and oncology concern Vir Biotechnology, Inc. ( VIR ) are down ~65% since enthusiasm generated from initial T cell engager data sparked a rally in January 2025. Its sole remaining infectious disease asset, a combination of tobevibart and elebsiran for CHD, has entered Phase 3 evaluation after producing superior results to clinical competitor bulevritide. With its stock trading at a significant discount to cash and EU-approved bulevritide likely to enjoy first-mover advantage in the U.S., this small-cap stock merited a deeper dive. An analysis follows below....

Read the full article on Seeking Alpha

For further details see: